KSV01 injection for relapsed DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new injection called KSV01 for people with a type of lymphoma (DLBCL) that has returned or not responded to previous treatments. The goal is to see if it can help shrink tumors or stop the disease from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment.
- Your lymphoma cells have a protein called CD19 on their surface (this is checked by your doctor).
- You are generally able to care for yourself (ECOG score 0 or 1) and your life expectancy is more than 3 months.
- You do not have active infections like hepatitis B, C, or HIV, or serious heart or brain conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (TRS005) combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) as a first treatment for people with CD20-positive DLBCL. The goal is to see if this combination is safe and effective in controlling the lymphoma.
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
This trial tests a new study treatment called KSD-101 for blood cancers linked to the Epstein-Barr virus (EBV) that have come back or not responded to other treatments. The goal is to see if it is safe and effective for people with these types of cancer.
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new drug called VK-2019 for people whose EBV-positive diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this drug can shrink tumors and help control the cancer.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.